PER® Winter Lung Cancer Conference | Conference

Targeted Agents Show Promise Against Emerging Oncogenic Drivers in NSCLC

January 28th 2019

Data on many new treatment options have come forward over the past year highlighting the potential to treat more emerging oncogenic drivers impacting smaller subsets of patients with non–small cell lung cancer.

Surgery Maintains Role in Rapidly Advancing Lung Cancer Treatment Paradigm

January 28th 2019

Eric Vallieres, MD, highlights the technological advances of lung cancer surgery and how this impacts the outlook for patients who are candidates for it.

Dr. Wakelee Discusses Current State of Treatment in NSCLC

January 27th 2019

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

Dr. Goldberg Discusses Treatment Approaches for Mesothelioma

January 27th 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses traditional and emerging treatment approaches for patients with mesothelioma.

Treatment Options Expand for ROS1, BRAF, and NTRK Alterations in NSCLC

January 27th 2019

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

EGFR-Targeted Activity Helps Differentiation Between TKIs in NSCLC

January 27th 2019

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

Lilenbaum Examines EGFR+ NSCLC Advancements and Potential Role of Immunotherapy

January 27th 2019

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer

January 26th 2019

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC

January 26th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

Naidoo Discusses Advances in the Management of Immunotherapy-Related AEs

March 13th 2018

Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.

Dr. Lopes Discusses the Importance of Addressing Financial Toxicity in Lung Cancer

March 13th 2018

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the important of addressing financial toxicity during the 5th Annual Miami Lung Cancer Conference.

Novel Agents Emerging for Lesser-Known Targets in NSCLC

March 13th 2018

ROS1, NTRK, MET, and HER2 are all less common molecular targets found in non–small cell lung cancer, but emerging therapeutic strategies are being explored to attack these abnormalities.

Dr. Wakelee on First-Line Therapy for EGFR-Mutant Lung Cancer

March 12th 2018

Heather Wakelee, MD, professor of medicine, division of oncology, Stanford University, discusses first-line therapy for patients with EGFR-mutant lung cancer.

BRAF V600E Testing Necessary in NSCLC, but Experts Unsure of Optimal Setting With BRAF/MEK Combo

March 12th 2018

Upfront testing for BRAF V600E mutations is necessary for patients with non–small cell lung cancer, but if results are positive, physicians are unsure when to administer BRAF/MEK combination therapy—and they must be prepared to manage the associated adverse events.

Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer

March 11th 2018

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

Dr. Naidoo Discusses the Management of Immune-Related Adverse Events in Lung Cancer

March 11th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

Dr. Brahmer Discusses Frontline Single-Agent Pembrolizumab in Lung Cancer

March 11th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in the first-line treatment of non–small cell lung cancer during the 5th Annual Miami Lung Cancer Conference.

Immunotherapy Making Headway in SCLC and Mesothelioma

March 11th 2018

Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.

Studies Highlight Rationale for Immunotherapy in Early-Stage and Locally Advanced NSCLC

March 11th 2018

With durvalumab (Imfinzi) being hailed as a potentially practice changing therapy in locally advanced non–small cell lung cancer, ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease.

Expert Addresses Global Disparities in Lung Cancer, Efforts to Bridge the Gap

March 8th 2018

Gilberto Lopes, MD, discusses the global disparities occurring in lung cancer care and some of the steps that are being taken to better serve patients with the available and emerging therapeutic approaches.